Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study

EXPERT OPINION ON BIOLOGICAL THERAPY · Published 2026-04-02 · DOI 10.1080/14712598.2026.2655440

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14712598.2026.2655440

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
The role of monoclonal antibodies in the treatment of lupus nephritis · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal